Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Enochian Biosciences Announces the Successful Completion of an FDA Pre-IND for A Potential Cure for HIV: The Second Pre-IND in 1 Month

10/18/2021 | 07:00am EST

Enochian BioSciences, Inc. announced the completion of an Investigator Pre-Investigational New Drug (IND) process following receipt of written comments from the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT).Dr. Serhat Gumruk?u, co-founder and inventor of Enochian BioSciences, and Director of Seraph Research Institute (SRI), submitted an investigator-initiated Pre-IND. The request was based on the results of a 54-year old man living with HIV who had failed to suppress the virus with antiviral therapy (ART). The patient subsequently stopped taking ART and received an innovative treatment developed by SRI. Enochian BioSciences holds the exclusive license for the product. The patient?s HIV infection blood levels were controlled more effectively for 365 consecutive days, off ART using this new innovative SRI treatment compared to what had previously been achieved with ART. The proprietary therapy includes Natural Killer (NK) and Gamma Delta T-cells (GDT) collected from another person. During the entire period, no antiviral drugs were given. It is believed that the GDT cells, a small subset of immune cells that can be infected with HIV, could be a key factor in controlling the virus.


ę S&P Capital IQ 2021
All news about ENOCHIAN BIOSCIENCES, INC.
11/15ENOCHIAN BIOSCIENCES INC Management's Discussion and Analysis of Financial Condition a..
AQ
11/15Enochian Biosciences, Inc. Reports Earnings Results for the First Quarter Ended Septemb..
CI
10/28Amendment to Annual Report (Form 10-K/A)
PU
10/19Enochian Biosciences, Inc. Announces Potential Cure for IV Successfully Completes Pre-I..
CI
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
PU
10/18ENOCHIAN BIOSCIENCES : Completes FDA Pre-IND for HIV Antiviral Therapy; Shares Down in Pre..
MT
10/18Enochian BioSciences Completes Pre-IND After FDA Comments
DJ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
AQ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 Month
CI
10/15ENOCHIAN BIOSCIENCES : Scientific Advisory Board Member Resigns Due to Conflict with Respo..
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash 2021 13,3 M - -
P/E ratio 2021 -9,71x
Yield 2021 -
Capitalization 573 M 573 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,9%
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.272.20%573
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678